Splash Image
About Us

Scientific Advisory Board

World-Class Expertise

Northern Biologics is rapidly advancing drug candidates in preparation for human clinical trials.

At the heart of this work is our talented Scientific Advisory Board:

Lee Babiss, PhD

Lee Babiss, PhD

Lee Babiss is Chief Scientific Officer and Executive Vice President of Global Laboratory Services at Pharmaceutical Product Development Inc. He was formerly President and Director of Pharmaceutical Research at F. Hoffmann-La Roche, Ltd. Prior to Roche; Lee spent seven years with Glaxo Inc., now GlaxoSmithKline, where he held senior positions, including Vice President of Biological Sciences and Genetics. He received his PhD in Microbiology from Columbia University and completed his postdoctoral fellowship at Rockefeller University, where he served as both an assistant and associate professor. He is an author on more than sixty publications. Lee has received numerous fellowship awards and grants and serves on several scientific advisory committees and boards.

Josep Baselga, MD, PhD

Josep Baselga, MD, PhD

Dr. Baselga is Physician-in-Chief at the Memorial Sloan-Kettering Cancer Center (MSKCC) and the AACR President-Elect. Dr. Baselga has conducted research that led to substantial improvements in survival for patients with multiple types of breast cancer. His works includes the clinical investigation of novel agents targeting the HER2 and EGF receptors. Dr. Baselga played a leading role in the pivotal clinical trials of trastuzumab, everolimus, lapatinib, and pertuzumab. Previously, he served as the Chairman of the Medical Oncology Service and Founding Director of the Vall d’Hebron Institute of Oncology (VHIO) at the Vall d’Hebron University Hospital in Barcelona. He also was the chief of the Division of Hematology/Oncology and associate director of the MGH Cancer Center in Massachusetts. Dr. Baselga is also past President of ESMO, past President of SOLTI and a past member of the Board of Directors of ASCO and AACR. Dr. Baselga received his MD degree from the Universidad Autonoma of Barcelona and completed a fellowship in Medical Oncology at MSKCC. During his career, Dr. Baselga has published more than 350 peer-reviewed articles and over 400 abstracts and book chapters.

Gianni Gromo, MD, PhD

Gianni Gromo, MD, PhD

Gianni is a Partner with Versant Ventures. Gianni previously served as a Senior Executive with several pharmaceutical companies, most recently Hoffmann-La Roche, where he successfully lead research and development teams. Gianni’s roles at Roche included Research Head of Global Cardiovascular and Metabolic Research, where he was responsible for all discovery and development activities in the CV, Renal and Metabolic areas; Head of Discovery Research, Basel Site; Global Head of the Metabolic and Vascular Disease Business Unit; and more recently Head of the Roche China R&D center, Shanghai. Prior to Roche, Gianni was Assistant Professor (tenure track), Immunobiology Research Center, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA; Research Director at Italfarmaco SpA, Milano, Italy; and Director of Biology-Cardiovascular-Lilly Research Laboratories, Indianapolis, Indiana, USA. He served as a Scientific Advisor to CSIRO (Australia), Baker Institute (Australia), Integra (Yissum/ Hebrew University, Israel)Momentum Fund (Ramot / Tel Aviv University). He serves on the Board of Directors of Novira Therapeutics (USA), and Piqur (Switzerland). Gianni received his MD and PhD in Clinical and Experimental Hematology at University of Milano, Italy.

Guido Magni, MD, PhD

Guido Magni, MD, PhD

Dr. Guido Magni is a Partner with Versant Ventures. Guido previously served as a Managing Director of EuroVentures, a Versant incubator, where he was intimately involved in several biotech investments including Synosia (sold to Biotie Therapies), Flexion and Okairos. Guido was previously the Global Head of the Medical Science Department of Roche Pharmaceuticals in Basel, Switzerland. During his twelve-year term at Roche, Guido oversaw the development and the registration of a large number of new chemical and biological entities including Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Currently, Guido serves on the Board of Biotie and AM Pharma, with previous board positions at Adolor Corporation and Anabasis Pharma before their recent acquisitions. Guido was trained at the University of Padua with a specialization in neuro-psychiatry. He is the co-author of over 100 peer-reviewed papers.

Ben Neel, MD, PhD

Ben Neel, MD, PhD

Ben Neel is the Director of the Laura and Isaac Perlmutter Cancer Center (LIPCC) and Professor of Medicine at NYU-Langone Medical School. Ben’s research focuses on cellular signal transduction, with a particular interest in the biology and regulation of protein-tyrosine kinases and phosphatases, the role of RAS/ERK pathway mutations in developmental disease and malignancy, and the functional genomics of breast and ovarian cancer.

Prior to LIPCC, Ben was the Director of Research at Princess Margaret Cancer Centre (PMCC), and Professor of Medical Biophysics and Tier 1 Canada Research Chair at the University of Toronto. Prior to PMCC, he was the William B. Castle Chair of Medicine at Harvard Medical School. Ben holds a PhD in Viral Oncology from Rockefeller University, and an MD from Cornell University.

Joan Seoane, PhD

Joan Seoane, PhD

Joan Seoane is currently the director of the Translational Research Program of the Vall d´Hebron Institute of Oncology (VHIO) integrated in the Vall d’Hebron University Hospital, head of the Gene Expression and Cancer Laboratory, and member of the Executive Board of VHIO. He is also an ICREA Research Professor and associate professor of the Autonomous University of Barcelona. He previously worked at the Memorial Sloan-Kettering Cancer as a Research Fellow and Research Associate. At VHIO, he has generated a multidisciplinary group focused on translational research in brain tumors. Joan’s group has identified several therapeutic targets against cancer, his publications have generated more than 4000 citations and has collaborated with several pharmaceutical companies (Eli Lilly, Novartis, MSD) to develop anti-cancer agents.